Direct oral anticoagulant and antiplatelet combination therapy: Hemorrhagic events in coronary artery stent recipients.

ABSTRACT: Direct oral anticoagulant (DOAC) use is growing as monotherapy and combined with platelet inhibitors. The safety of such combination therapy, especially in comparison to regimens including warfarin, in real world populations remains uncertain. We investigated hemorrhage associated with DOAC and antiplatelet combination therapy in a cohort of elderly coronary artery stent recipients. We employed Medicare data 2010-2013 for a 40% random sample of beneficiaries enrolled in inpatient, outpatient and prescription benefits. We used Cox proportional hazards models to examine the association of the combination anticoagulant (DOAC or warfarin) plus antiplatelets with major hemorrhage events (upper gastrointestinal or intracranial) in the 12 months following stent placement. We identified 70,900 ste

SUBMITTER: Bekelis K 

PROVIDER: S-EPMC5936642 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature